除了脂质:在糖尿病视网膜病变和神经病变中使用 fenofibrate
Mengying Liu1, Seok Ting Lim2, Weihua Song3
1Duke-NUS Medical School, Singapore 169857, Singapore.; Singapore Eye Research Institute, Singapore 169856, Singapore.
Trends in pharmacological sciences
|August 20, 2025
概括
纤维酸盐通过减少炎症和氧化应激减轻糖尿病视网膜病变和病的治疗有望,提供超出脂质控制的好处. 本综述探讨了糖尿病微血管并发症的机制和临床潜力.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 眼科医生 眼科 眼科
背景情况:
- 糖尿病视网膜病变 (DR) 和病变 (DN) 是严重的糖尿病并发症,治疗选择有限.
- 费诺纤维酸,PPAR-α激动剂,表现出对视网膜和脏的保护作用,超出其降脂能力.
- 临床前和临床研究揭示了费诺纤维酸的性作用,包括抗炎,抗氧化,神经保护和抗纤维作用.
研究的目的:
- 审查机制性见解和临床证据,支持纤维酸在糖尿病微血管并发症中的疗效.
- 探索参与费诺纤维酸的保护作用的PPAR-α依赖性和独立性途径.
- 确定新出现的分子标,并提出推进纤维酸在DR和DN的临床应用的策略.
主要方法:
- 检讨了研究纤维酸的作用机制的临床前研究.
- 对临床试验数据的分析,评估纤维酸对糖尿病视网膜病变和病变的影响.
- 整合机理学数据与临床结果,以评估治疗潜力.
主要成果:
- 费诺纤维酸对糖尿病微血管损伤具有多方面的保护作用.
- 这些好处归因于抗炎,抗氧化,神经保护和抗纤维素性质.
- 即使在血脂水平正常的患者中,纤维酸也可能有益.
结论:
- 费诺纤维酸在治疗糖尿病视网膜病变和病症方面具有显著的潜力.
- 它的类作用为糖尿病微血管并发症提供了一个有希望的治疗途径.
- 进一步的研究和战略性临床应用是有必要的,以优化芬诺纤维酸的使用.
关键词:
糖尿病性脏病 糖尿病脏病糖尿病视网膜病变 糖尿病视网膜病变药物重用是为了改变药物的用途.芬诺纤维酸盐的使用方法纳米颗粒配方的制剂氧酶增殖器激活受体-α (PPAR-α) agonist 的作用.更多相关视频
10:07Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
Published on: December 26, 2017
13.5K
04:36Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression
Published on: January 12, 2024
1.2K
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
869
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
869
01:25Antihypertensive Drugs: Direct Renin Inhibitors
819
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
819
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
875
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
875
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291
01:23Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
01:24Chronic Kidney Disease II: Clinical Manifestations
87
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
87